CS585 is a novel, potent and selective prostacyclin receptor agonist (IP receptor agonist) in preclinical development targeting rare thrombotic diseases with significant unmet medical need. In preclinical studies conducted to date, CS585 has demonstrated the ability to prevent thrombosis without increasing bleeding risk and exhibit a long-lasting effect of more than 24 hours. This is a highly differentiated profile compared to currently available antithrombotic therapies. The planned APS-focused studies are intended to further evaluate CS585’s therapeutic potential in a disease characterized by recurrent thrombosis and limited treatment options. The studies will be led by Professor Michael Holinstat, Director of Translational Research at Cereno Scientific and Professor at the University of Michigan.

“CS585 has consistently demonstrated compelling antithrombotic effects in preclinical studies while preserving normal hemostasis, which is a highly desirable profile in thrombotic disease,” said Mike Holinstat, Director of Translational Research at Cereno Scientific and Professor at the University of Michigan. “APS represents a scientifically and clinically relevant disease model for further evaluating the candidate’s therapeutic potential and to progress toward clinical phase.”

APS is a rare autoimmune disorder in which the immune system mistakenly produces antibodies that increase the risk of blood clot formation. Patients with APS face elevated risk of deep vein thrombosis, stroke, pulmonary embolism, pregnancy-related complications, and organ damage. Current standard-of-care treatment primarily relies on chronic anticoagulation therapy, which may reduce thrombotic risk but can also significantly increase bleeding risk and require burdensome long-term monitoring.

“Advancing CS585 into disease models of APS marks continued progress for Cereno Scientific as we expand our pipeline of innovative therapies for rare cardiovascular diseases,” said Sten R. Sörensen, CEO of Cereno Scientific. “The market for safer and more effective long-term antithrombotic therapies in rare thrombotic diseases remains highly underserved, creating a significant opportunity for CS585.”

The preclinical APS studies are planned to be initiated during 2026 through Cereno Scientific’s ongoing research collaboration with the University of Michigan. The data generated are expected to support future development planning and continued evaluation of CS585 toward clinical development.